Medical Disclaimer

Weight Loss Rankings is an educational publisher, not a healthcare provider. The content on WeightLossRankings.org — including our research articles, drug interaction checker, BMI calculator, weight loss calculator, dose plotters, savings calculators, washout calculator, provider directories, and any other tool or page on this site — is published for general educational and informational purposes only. It is not, and should not be treated as, medical advice, a medical diagnosis, a treatment recommendation, or a substitute for the professional judgment of a qualified healthcare provider.

Always consult a qualified healthcare provider

Always seek the advice of your physician, nurse practitioner, physician assistant, pharmacist, or other qualified healthcare provider with any questions you may have regarding a medical condition, a medication, a dose, an interaction, a side effect, or any decision to start, stop, switch, or modify a treatment. Never disregard professional medical advice or delay seeking it because of something you have read on Weight Loss Rankings.

In case of a medical emergency, call 911

If you are experiencing a medical emergency — including but not limited to severe abdominal pain, persistent vomiting, signs of dehydration, signs of a severe allergic reaction, signs of pancreatitis, severe hypoglycemia, sudden vision changes, chest pain, difficulty breathing, or any other acute medical concern — call 911 or go to your nearest emergency department immediately. Do not use Weight Loss Rankings to diagnose or self-manage an acute medical situation.

We are not your prescriber, your pharmacy, or your telehealth provider

Weight Loss Rankings does not write prescriptions, dispense medication, conduct clinical examinations, deliver telehealth services, or establish a doctor-patient relationship of any kind with our readers. Use of this website does not create a healthcare provider-patient relationship between you and Weight Loss Rankings, its writers, its editors, or its operators. The provider directories and ranked lists we publish are independent reviews; we link to third-party providers but do not vouch for the medical care those providers deliver. Verify any provider directly before signing up.

Drug information is sourced from FDA labels and PubMed

The clinical claims, trial data, dose information, side effect rates, and drug interaction entries on this site are sourced from the FDA-approved prescribing information (the official label) for each drug, the published peer-reviewed clinical trial literature (NEJM, JAMA, Lancet, BMJ, etc.), the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, the American Society of Anesthesiologists, the American Diabetes Association, the Obesity Medicine Association, and other recognized clinical authorities. Where we cite a number, we cite the source. We intentionally avoid anecdotal or unverified claims as the basis for clinical content.

Even with rigorous sourcing, our content may contain errors, omissions, or out-of-date information. Drug labels are updated frequently. Trial data is reanalyzed and republished. New side effect signals emerge. New drugs receive approval (such as the April 2026 Foundayo / orforglipron approval). We update our content as we become aware of changes, but we cannot guarantee that every page is current as of the moment you read it. Always confirm clinically meaningful information with the most recent FDA-approved prescribing information for the drug in question and with your prescribing clinician.

Individual outcomes vary

The trial-reported weight loss percentages, side effect rates, half-lives, blood pressure changes, and other clinical figures we cite are population means from the registration trials. Individual patient outcomes vary substantially based on starting weight, age, sex, body composition, comorbidities, concurrent medications, dose, adherence, lifestyle, genetics, and many other factors. The fact that the average STEP-1 patient lost 14.9% of body weight on semaglutide 2.4 mg (or that the average SURMOUNT-1 patient lost 20.9% on tirzepatide 15 mg, or that the average ATTAIN-1 patient lost 11.1% at the labeled 17.2 mg dose of orforglipron) does not mean that you will. Roughly 10-15% of trial participants lost less than 5% even at the maintenance dose, and another 10-15% lost considerably more. Our weight loss calculator, BMI calculator, and other prediction tools are educational extrapolations of trial data — they are not personalized medical predictions.

Pricing and availability change frequently

The pricing tiers, savings card amounts, formulary inclusion, insurance coverage, and provider availability we publish are accurate as of the publication date stated on each page. The GLP-1 market is unusually volatile — manufacturer programs change, insurance formularies update annually or more frequently, compounded telehealth providers come and go, and FDA shortage status flips. Always verify current pricing and availability directly with the provider, pharmacy, or insurer before signing up or paying.

Drug interactions, contraindications, and warnings

Our GLP-1 drug interaction checker and our research articles discuss known interactions, contraindications, and warnings sourced from the FDA-approved prescribing information. This is not an exhaustive interaction database and is not a substitute for the real-time drug interaction checking your pharmacist performs when you fill a prescription. Always tell every prescriber and every pharmacist about every medication, supplement, and over-the-counter product you take, and confirm any specific interaction with them before starting or stopping anything.

The boxed warnings, contraindications, and clinically significant warnings that apply to GLP-1 receptor agonists include but are not limited to: medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia syndrome type 2 (MEN2), acute pancreatitis, acute kidney injury, hypoglycemia (especially in combination with insulin or sulfonylureas), gallbladder disease, diabetic retinopathy complications in patients with type 2 diabetes, hypersensitivity reactions, and pulmonary aspiration risk under general anesthesia. Read the actual FDA-approved prescribing information for the specific drug you have been prescribed and discuss every concern with your prescribing clinician.

Pregnancy, breastfeeding, and reproductive health

GLP-1 receptor agonists are generally not recommended during pregnancy or breastfeeding, and the Wegovy prescribing information recommends discontinuing semaglutide at least two months before a planned pregnancy. If you are pregnant, breastfeeding, planning to become pregnant, or could become pregnant, do not start, continue, or stop a GLP-1 based on anything you read on Weight Loss Rankings — discuss the decision with your obstetrician, your endocrinologist if applicable, and your prescribing clinician.

No off-label or non-FDA-approved-use guidance

We do not recommend, endorse, or instruct on off-label dosing, microdosing, splitting weekly doses, combining medications outside of FDA-approved indications, or any use of GLP-1 receptor agonists that is inconsistent with the FDA-approved prescribing information. Where we discuss off-label practices in our articles (such as the tirzepatide microdosing evidence guide or the phentermine-plus-GLP-1 combination article), we do so as educational summaries of what the published evidence shows and what some prescribers do — not as recommendations. Off-label decisions are between you and a qualified prescriber, not between you and a website.

Affiliate relationships

Weight Loss Rankings is reader-supported. When you click on a provider link from our site and sign up or make a purchase, we may receive a commission at no additional cost to you. We disclose these relationships on every relevant page. Affiliate compensation does not influence our editorial process, our trial-data citations, our drug interaction database, our safety warnings, or our ranked provider lists. See our full affiliate disclosure and our nature-of-reviews methodology for the full editorial framework.

Limitation of liability

To the fullest extent permitted by law, Weight Loss Rankings, its operators, its writers, its editors, and its affiliates disclaim all warranties — express or implied — relating to the content on this website, including but not limited to warranties of accuracy, completeness, fitness for a particular purpose, and non-infringement. We are not liable for any harm, injury, loss, damage, or adverse outcome arising from your use of, reliance on, or inability to use the content on this website. Your use of this website constitutes your acknowledgment and acceptance of this disclaimer.

Reporting an error

We take YMYL accuracy seriously. If you believe a clinical claim, a trial number, a drug interaction entry, a dose, a price, or any other piece of information on Weight Loss Rankings is incorrect or out of date, please contact us via our contact page and we will review and correct it. Please include the URL of the page, the specific claim in question, and the source you believe is authoritative for the correction.

Acceptance

By using WeightLossRankings.org, you acknowledge that you have read, understood, and agreed to this Medical Disclaimer in addition to our Terms of Service and Privacy Policy. If you do not agree with any portion of this disclaimer, please do not use this website.